[1]王丹辉,贲越,韩梅.林蛙油治疗绝经后骨质疏松症的临床研究[J].中医正骨,2014,26(01):27-30.
　Wang Danhui*,Ben Yue,Han Mei..Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(01):27-30.
点击复制

林蛙油治疗绝经后骨质疏松症的临床研究()
分享到：

《中医正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第26卷
期数:
2014年01期
页码:
27-30
栏目:
临床研究
出版日期:
2014-01-28

文章信息/Info

Title:
Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis
作者:
王丹辉1; 贲越2; 韩梅3
1.吉林省中医药科学院,吉林 长春 130021;
2.吉林省长春市中医院,吉林 长春 130021;
3.广东省广州市红十字会医院,广东 广州 510000
Author(s):
Wang Danhui*; Ben Yue; Han Mei.
*Jilin Academy of Traditional Chinese Medical Sciences,Changchun 130021,Jilin,China
关键词:
骨质疏松; 绝经后 林蛙 仙灵骨葆胶囊 治疗; 临床研究性 骨密度 碱性磷酸酶 骨钙素 雌二醇 白细胞介素6
Keywords:
Osteoporosis; postmenopausal;  Rana temporaria;  XIANLING GUBAO capsule;  Therapies; investigational;  Bone Density;  Alkaline phosphatase;  Osteocalcin;  Estradiol;  Interleukin-6
摘要:
目的:观察林蛙油治疗绝经后骨质疏松症的临床疗效,并探讨其作用机制。方法:将60例绝经后骨质疏松症患者随机分为治疗组和对照组,每组30例,治疗组采用口服林蛙油治疗,对照组采用口服仙灵骨葆胶囊治疗。治疗6个月后,观察2组患者治疗前后临床症状体征评分改变及骨密度、骨代谢指标变化情况。结果:①症状体征评分。治疗前2组患者症状体征评分比较,差异无统计学意义(t=1.781,P=0.113); 治疗6个月后,2组患者症状体征评分均较治疗前降低[(17.67±3.67)分,(6.44±2.46)分,t=13.808,P=0.000;(20.22±2.17)分,(11.89±1.90)分,t=15.811,P=0.007],治疗组降低更明显 [(11.23±2.44)分,(8.33±1.58)分,t=2.760,P=0.025]。②骨密度。治疗前和治疗6个月后,2组患者骨密度比较,组间差异均无统计学意义(t=0.824,P=0.425; t=0.767,P=0.457); 治疗6个月后,2组患者骨密度与治疗前比较,差异均无统计学意义[(-2.37±0.84)g·cm-2,(-2.65±0.91)g·cm-2,t=0.811,P=0.432;(-2.19±0.83)g·cm-2,(-2.41±0.56)g·cm-2,t=0.727,P=0.479]。③骨代谢指标。治疗前2组患者骨碱性磷酸酶、雌二醇、白细胞介素-6、骨钙素血清含量比较,组间差异均无统计学意义(t=1.622,P=0.127; t=1.114,P=0.284; t=1.554,P=0.143; t=1.185,P=0.160)。治疗6个月后,2组患者血清骨碱性磷酸酶含量[(17.13±2.13)单位·L-1,(7.80±1.82)单位·L-1,t=12.594,P=0.000;(16.40±1.80)单位·L-1,(10.73±2.12)单位·L-1,t=8.324,P=0.000]、血清白细胞介素-6含量[(125.20±13.86)μg·L-1,(88.13±10.20)μg·L-1,t=5.795,P=0.000;(131.93±11.07)μg·L-1,(107.40±7.74)μg·L-1,t=9.648,P=0.000]、血清骨钙素含量[(6.19±0.96)ng·L-1,(3.54±1.12)ng·L-1,t=6.504,P=0.000;(5.80±0.56)ng·L-1,(5.15±0.51)ng·L-1,t=6.733,P=0.000]均较治疗前降低,治疗组降低更明显[(9.33±2.87)单位·L-1,(5.67±2.64)单位·L-1,t=7.416,P=0.000;(37.17±19.08)μg·L-1,(24.53±9.85)μg·L-1,t=2.253,P=0.041;(2.65±1.53)ng·L-1,(0.64±0.37)ng·L-1,t=4.820,P=0.000]; 2组患者血清雌二醇含量均较治疗前升高[(21.73±5.55)pg·mL-1,(43.40±5.65)pg·mL-1,t=8.208,P=0.000;(24.27±7.72)pg·mL-1,(34.13±5.75)pg·mL-1,t=5.006,P=0.000],治疗组升高更明显[(21.67±10.22)pg·mL-1,(9.87±7.63)pg·mL-1,t=4.209,P=0.001]。结论:林蛙油在短期内未能提高绝经后骨质疏松症患者的骨密度,但可以明显提高其血清雌二醇水平,降低其血清骨碱性磷酸酶、白细胞介素-6和骨钙素水平,这可能是林蛙油可以明显改善PMOP患者的临床症状与体征的作用机制之一。
Abstract:
Objective:To observe the clinical effects of Rana temporaria oil on postmenopausal osteoporosis(PMOP)and to explore its mechanisms of action.Methods:Sixty patients with PMOP were randomly divided into treatment group and control group,30 cases in each group.The patients in treatment group were treated with Rana temporaria oil,while the others in control group were treated with XIANLING GUBAO capsules.The changes in clinical symptoms and signs scores,bone density and bone metabolism index were observed and compared between the 2 groups before and after 6-month treatment.Results:There were no statistical difference in the symptoms and signs scores between the 2 groups before the treatment(t=1.781,P=0.113).while the symptoms and signs scores decreased in both of the 2 groups after 6-month treatment(17.67+/-3.67 vs 6.44+/-2.46 points,t=13.808,P=0.000; 20.22+/-2.17 vs 11.89+/-1.90 points,t=15.811,P=0.007),and the scores decreased more significantly in the treatment group(11.23+/-2.44 vs 8.33+/-1.58 points,t=2.760,P=0.025).There were no statistical difference in bone density between the 2 groups before the treatment and after 6-month treatment(t=0.824,P=0.425; t=0.767,P=0.457).There were no statistical difference in bone density between pre- and post-treatment(-2.37+/-0.84 vs -2.65+/-0.91 g/cm(2),t=0.811,P=0.432; -2.19+/-0.83 vs -2.41+/-0.56 g/cm(2),t=0.727,P=0.479).There were no statistical difference between the 2 groups in the serum concentrations of bone alkaline phosphatase,estradiol,interleukin-6 and osteocalcin before the treatment(t=1.622,P=0.127; t=1.114,P=0.284; t=1.554,P=0.143; t=1.185,P=0.160).The serum concentrations of bone alkaline phosphatase(17.13+/-2.13 vs 7.80+/-1.82 units/L,t=12.594,P=0.000; 16.40+/-1.80 vs 10.73+/-2.12 units/L,t=8.324,P=0.000),interleukin-6(125.20+/-13.86 vs 88.13+/-10.20 μg/L,t=5.795,P=0.000; 131.93+/-11.07 vs 107.40+/-7.74 μg/L,t=9.648,P=0.000)and osteocalcin(6.19+/-0.96 vs 3.54+/-1.12 ng/L,t=6.504,P=0.000; 5.80+/-0.56 vs 5.15+/-0.51 ng/L,t=6.733,P=0.000)decreased in both of the 2 groups after 6-month treatment,and more significant decrease were found in the treatment group(9.33+/-2.87 vs 5.67+/-2.64 units/L,t=7.416,P=0.000; 37.17+/-19.08 vs 24.53+/-9.85 μg/L,t=2.253,P=0.041; 2.65+/-1.53 vs 0.64+/-0.37 ng/L,t=4.820,P=0.000); The serum concentrations of estradiol increased in both of the 2 groups after 6-month treatment(21.73+/-5.55 vs 43.40+/-5.65 pg/mL,t=8.208,P=0.000; 24.27+/-7.72 vs 34.13+/-5.75 pg/mL,t=5.006,P=0.000),and more significant increase were found in the treatment group(21.67+/-10.22 vs 9.87+/-7.63 pg/mL,t=4.209,P=0.001).Conclusion:Although the Rana temporaria oil can not improve bone mineral density in patients with postmenopausal osteoporosis in short period,it can increase the serum estradiol level significantly and decrease the serum concentrations of bone specific alkaline phosphatase,interleukin-6 and osteocalcin,which may be one of the mechanisms of action for Rana temporaria oil to obviously improve clinical symptoms and signs of PMOP patients.

参考文献/References:

[1] 指导原则编写委员会.中药防治骨质疏松症及其骨折的临床前和临床评价指导原则[M].北京:人民卫生出版社,2006:1.
[2] 徐晓娟,沈霖,杨艳萍,等.青娥丸对绝经后骨质疏松症患者骨密度和骨转换标志物的影响[J].中国中医骨伤科杂志,2013,21(6):8-10.
[3] 刘忠厚,杨定焯,朱汉民,等.中国人骨质疏松症建议诊断标准(第二稿)[J].中国骨质疏松杂志,2000,6(1):1-3.
[4] 郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:356-360.
[5] Nelson HD,Walker M,Zakher B,et al.Menopausal hormone therapy for the primary prevention of chronic conditions:a systematic review to update the U.S. Preventive Services Task Force recommendations[J].Ann of Intern Med, 2012,157(2):104-113.
[6] 陈名道,杨颖.绝经妇女激素替代治疗的困境与中医药治疗更年综合征的前景[J].中西医结合学报,2003,1(1):9-11.
[7] 王春霖,王丽兰,姜言功.蛤士蟆油甾体性激素定量分析及药理作用[J].中药通报,1985,10(2):44.
[8] 王丹辉,王照辉,吴巍,等.林蛙油含药血清对成骨细胞和破骨细胞增殖和活性的影响[J].中国骨质疏松杂志,2010(5):318-321.
[9] Wang DH,Wu W,Tian JM, et al.Effect of oviductus ranae and oviductus ranae eggs on bone metabolism and osteoporosis[J].Chin J of Integr Med,2013,19(7):532-538.
[10] 刘忠厚.骨质疏松学[M ].北京:科学出版社,1998:217-219.
[11] 劳瑞平,孙桂荷,孙艳红.补肾健脾活血法对绝经后骨质疏松症患者骨碱性磷酸酶的影响[J].光明中医,2012,27(10):1983-1984.
[12] 张华,陈敢峰,吴俊哲,等.绝经后骨质疏松症血清中Leptin、NO、IL-6、BGP及E2的检测意义[J].中国中医骨伤科杂志,2008,16(2):1- 3.
[13] 吴连国,刘康,王定,等.强骨饮治疗骨关节炎合并骨质疏松患者的临床研究[J].中国中医骨伤科杂志,2011,19(12):10-13.

相似文献/References:

[1]李林军.应用膨胀式椎弓根螺钉内固定治疗合并骨质疏松的 胸腰椎退行性疾病[J].中医正骨,2015,27(08):49.
[2]韩艳,温利平,刘娜,等.补肾活血方对去卵巢大鼠骨代谢及骨密度的影响[J].中医正骨,2015,27(12):7.
　HAN Yan,WEN Liping,LIU Na,et al.Effect of Bushen Huoxue Fang(补肾活血方)on bone metabolism and bone mineral density in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(01):7.
[3]李学朋,朱立国.骨疏康胶囊对去卵巢大鼠骨小梁的影响[J].中医正骨,2015,27(12):12.
　LI Xuepeng,ZHU Liguo.Effect of Gushukang Jiaonang(骨疏康胶囊)on bone trabecula in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(01):12.
[4]陈冠军,陈扬,庄汝杰.可灌注骨水泥椎弓根螺钉系统 在老年腰椎疾患手术中的应用[J].中医正骨,2015,27(02):40.
[5]黄建华,黄建武,李慧辉,等.加味左归丸对绝经后骨质疏松症肝肾不足证 患者骨密度的影响[J].中医正骨,2013,25(11):19.
　Huang Jianhua*,Huang Jianwu,Li Huihui,et al.Effect of JIAWEI ZUOGUI pill on bone mineral density in postmenopausal osteoporosis patients with deficiency of liver and kidney[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(01):19.
[6]项旻,杨虹,林爱菊,等.绝经后2型糖尿病患者骨质疏松与血微量元素的关系研究[J].中医正骨,2013,25(12):20.
　Xiang Min*,Yang Hong,Lin Aiju,et al.Clinical study on the relationship between osteoporosis and serum trace elements levels in postmenopausal women with type 2 diabetes[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(01):20.
[7]史晓林,李春雯,张志强.弱阳离子磁珠分离技术和基质辅助激光解吸电离飞行时间质谱技术在原发性Ⅰ型骨质疏松症血清标志蛋白筛选中的应用[J].中医正骨,2014,26(03):5.
　Shi Xiaolin*,Li Chunwen,Zhang Zhiqiang..Application of magnetic beads based weak cation exchange separation technology and matrix-assisted laser desorption-ionization time of flight mass spectrometry technology in screening serum protein markers of primary type-Ⅰ osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(01):5.
[8]李明,徐明雄,冯左基,等.自拟壮骨方治疗绝经后骨质疏松症的疗效及作用机制研究[J].中医正骨,2014,26(09):21.
　Li Ming*,Xu Mingxiong,Feng Zuoji,et al.Study on the curative effect and mechanism of action of self-made ZHUANGGU decoction in treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(01):21.
[9]陈俊杰,李晴晴,夏瑢.脂代谢及血清内脂素水平与绝经后骨质疏松症的 相关性研究[J].中医正骨,2012,24(04):16.
　CHEN Jun-jie*,LI Qing-qing,XIA Rong.*.Study on the correlations between the levels of lipid metabolism and serum visfatin and postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(01):16.
[10]许超,肖鲁伟,吴承亮.绝经后女性骨质疏松症辨证分型与抑郁焦虑的关系研究[J].中医正骨,2011,23(12):3.
　XU Chao*,XIAO Lu-wei,WU Cheng-liang.*.Study on the relationship between the syndrome differ classification and the depression and anxiety for the postmenopausal women with osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2011,23(01):3.

更新日期/Last Update: 2014-01-20